Eton Pharmaceuticals (ETON) Long-Term Deferred Tax (2018 - 2024)

Eton Pharmaceuticals has disclosed Long-Term Deferred Tax across 5 years of filings, most recently posting $404000.0 for Q4 2024.

• Long-Term Deferred Tax for Q4 2024 came in at $404000.0, up 139.05% year-over-year; the trailing twelve-month figure through Dec 2024 was $404000.0 (up 139.05% YoY), and the FY2024 annual result was $404000.0, up 139.05% from the prior year.
• Long-Term Deferred Tax came in at $404000.0 for Q4 2024 at Eton Pharmaceuticals, up from $169000.0 in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $18.5 million in Q4 2021 to a low of $169000.0 in Q4 2023.
• The 3-year median for Long-Term Deferred Tax is $404000.0 (2024), against an average of $6.4 million.
• Peak annual rise in Long-Term Deferred Tax reached 139.05% in 2024, while the deepest fall reached 139.05% in 2024.
• Eton Pharmaceuticals' Long-Term Deferred Tax stood at $18.5 million in 2021, then sank by 99.09% to $169000.0 in 2023, then soared by 139.05% to $404000.0 in 2024.
• The last three Long-Term Deferred Tax figures came in at $404000.0 (Q4 2024), $169000.0 (Q4 2023), and $18.5 million (Q4 2021), per Business Quant data.